Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$28.71 USD

28.71
28,634,708

-0.17 (-0.59%)

Updated Aug 15, 2024 04:01 PM ET

Pre-Market: $28.64 -0.07 (-0.24%) 8:20 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know

Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Pfizer (PFE) Flat As Market Sinks: What You Should Know

Pfizer (PFE) closed the most recent trading day at $29.73, making no change from the previous trading session.

Pfizer (PFE) Surpasses Market Returns: Some Facts Worth Knowing

In the most recent trading session, Pfizer (PFE) closed at $28.61, indicating a +0.7% shift from the previous trading day.

Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It

Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Nod to AZN's Eplontersen, CRL to MRK's Cough Candidate

FDA approves AstraZeneca (AZN) and Ionis' (IONS) Wainua (eplontersen) for ATTRv-PN and gives CRL to Merck's chronic cough candidate, gefapixant.

FDA Accepts Merck's (MRK) BLA for 21-Valent Pneumococcal Jab

The FDA grants priority review to Merck's (MRK) filing seeking approval for its 21-valent pneumococcal conjugate vaccine in adults. A final decision is expected in June 2024.

Pfizer (PFE) Stock Rises on FDA Nod for Expanded Use of Padcev

The FDA approves Pfizer's (PFE) Padcev in combination with Merck's (MRK) Keytruda for adult patients with advanced bladder cancer. Stock rises 1.6%.

Pfizer (PFE) Beats Stock Market Upswing: What Investors Need to Know

The latest trading day saw Pfizer (PFE) settling at $27.06, representing a +1.61% change from its previous close.

Kinjel Shah headshot

Pharma Stock Roundup: PFE Issues Weak 2024 View, AZN to Buy Icosavax & More

Pfizer (PFE) issues a disappointing outlook for 2024. AstraZeneca (AZN) announces that it is buying vaccine company, Icosavax.

Company News for Dec 14, 2023

Companies in The News Are: ABM,PFE,HD,GS

Pfizer (PFE) Stock Sinks on Weak 2024 View as COVID Sales Fall

Pfizer's (PFE) shares decline almost 7% in response to the muted guidance for 2024. Revenues are expected to be in the range of $58.5 to $61.5 billion, while adjusted EPS is expected in the range of $2.05 to $2.25.

The Zacks Analyst Blog Highlights The Home Depot, Advanced Micro Devices, Pfizer, The Cigna Group and Live Nation Entertainment

The Home Depot, Advanced Micro Devices, Pfizer, The Cigna Group and Live Nation Entertainment are part of the Zacks top Analyst Blog.

Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know

Pfizer (PFE) concluded the recent trading session at $28.58, signifying a -0.21% move from its prior day's close.

Sheraz Mian headshot

Top Stock Reports for Home Depot, Advanced Micro Devices & Pfizer

Today's Research Daily features new research reports on 16 major stocks, including The Home Depot, Inc. (HD), Advanced Micro Devices, Inc. (AMD) and Pfizer Inc. (PFE).

Pfizer's (PFE) Hemophilia Candidate BLA Gets FDA Acceptance

The FDA decision on Pfizer's (PFE) BLA for marstacimab for hemophilia A and B is expected in the fourth quarter of 2024, while the European Commission's decision is expected in 2025.

Pfizer's (PFE) Multiple Myeloma Drug Elrexfio Gets Nod in EU

Pfizer's (PFE) targeted immunotherapy, Elrexfio, for treating heavily pretreated adults with relapsed/refractory multiple myeloma gets EC's conditional marketing authorization.

Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know

Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.

Kinjel Shah headshot

Pharma Stock Roundup: ABBV to Buy CERE, JNJ's 2024 View, LLY & NVS Get FDA Nod

AbbVie (ABBV) offers to acquire Cerevel Therapeutics for $8.7 billion. J&J (JNJ) announces sales and earnings growth expectations for 2024.

Zacks Market Edge Highlights: SAIC, ANET, LLY, PFE and SIG

SAIC, ANET, LLY, PFE and SIG have been highlighted in this Market Edge article.

Tracey Ryniec headshot

Will There Be a Recession in 2024?

Tracey Ryniec and John Blank examine whether a recession is looming and how to invest in the new year.

Pfizer (PFE) Declines More Than Market: Some Information for Investors

In the most recent trading session, Pfizer (PFE) closed at $28.79, indicating a -1.03% shift from the previous trading day.

Pfizer (PFE), Arvinas Post Upbeat Data From Breast Cancer Study

Interim data from an early-stage study shows that treatment with Pfizer (PFE)/Arvinas' (ARVN) breast cancer combination therapy demonstrates encouraging clinical activity in heavily pre-treated patients.

Roche (RHHBY) Breast Cancer Drug Meets Primary Goal in Phase III

Roche's (RHHBY) phase III study evaluating inavolisib in combination with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation achieves its primary goal.

Roche (RHHBY) to Acquire Obesity Drug Maker Carmot for $2.7B

Roche (RHHBY) aims to enter the promising and much-in-demand obesity drug market with the acquisition of Carmot Therapeutics, Inc. for $2.7 billion.

Altimmune (ALT) Rises 83% on Successful Phase II Obesity Study

Altimmune (ALT) reports positive top-line data from its 48-week phase II MOMENTUM study of obesity drug candidate, pemvidutide. The stock gains 83%.